Key points are not available for this paper at this time.
Dual-target drug design addresses complex diseases and drug resistance, yet existing computational approaches struggle with simultaneous multi-protein optimization. This study presents SFG-Drug, a novel dual-target molecular generation model combining Monte Carlo tree search with gated recurrent unit neural networks for simultaneous MEK1 and mTOR targeting. The methodology employed DigFrag digital fragmentation on ZINC-250k dataset, integrated low-frequency masking techniques for enhanced diversity, and utilized molecular docking scores as reward functions. Comprehensive evaluation on MOSES benchmark demonstrated superior performance compared to state-of-the-art methods, achieving perfect validity (1.000), uniqueness (1.000), and novelty (1.000) scores with highest internal diversity indices (0.878 for IntDiv1, 0.860 for IntDiv2). Over 90% of generated molecules exhibited favorable binding affinity with both targets, showing optimal drug-like properties including QED values in 0.2, 0.7 range and high synthetic accessibility scores. Generated compounds demonstrated structural novelty with Tanimoto coefficients below 0.25 compared to known inhibitors while maintaining dual-target binding capability. The SFG-Drug model successfully bridges the gap between computational prediction and practical drug discovery, offering significant potential for developing new dual-target therapeutic agents and advancing AI-driven pharmaceutical research methodologies.
Li et al. (Mon,) studied this question.